Smith & Nephew plc (SNNUF)
| Market Cap | 12.57B -20.2% |
| Revenue (ttm) | 6.30B +6.0% |
| Net Income | 635.00M +29.3% |
| EPS | 0.74 +31.8% |
| Shares Out | n/a |
| PE Ratio | 19.80 |
| Forward PE | 12.90 |
| Dividend | 0.39 (2.53%) |
| Ex-Dividend Date | Mar 26, 2026 |
| Volume | 300 |
| Open | 15.70 |
| Previous Close | 15.48 |
| Day's Range | 15.48 - 15.75 |
| 52-Week Range | 13.10 - 18.50 |
| Beta | 0.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial StatementsNews
Smith & Nephew SNATS Q2 Earnings Call Highlights
Smith & Nephew SNATS NYSE: SNN reported second-quarter underlying revenue growth of 1.6%, below management's expectations, as continued strength in Sports Medicine and ENT was offset by weakness in U....
Smith & Nephew price target lowered to 1,250 GBp from 1,350 GBp at RBC Capital
RBC Capital lowered the firm’s price target on Smith & Nephew to 1,250 GBp from 1,350 GBp and keeps a Sector Perform rating on the shares.
Smith & Nephew price target lowered to 1,250 GBp at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Smith & Nephew to 1,250 GBp from 1,400 GBp and keeps a Hold rating on the shares.
Smith & Nephew downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Smith & Nephew to Neutral from Overweight with a price target of 1,290 GBp, down from 1,438 GBp. The company is seeing a “material and broad” slowdown, the…
Smith & Nephew price target lowered to 1,304 GBp at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Smith & Nephew to 1,304 GBp from 1,333 GBp and keeps an Overweight rating on the shares. Published first…
Smith+Nephew celebrates mobility, recovery and football's greatest traditions during Pro Football Hall of Fame Enshrinement Week
Canton, Ohio—As thousands of football fans descend on Canton for the 2026 Pro Football Hall of Fame Enshrinement Week, Smith+Nephew, the Global medical technology company, will join the celebration wi...
Smith & Nephew downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded Smith & Nephew to Underweight from Equal Weight with a price target of 1,050 GBp, down from 1,290 GBp. The firm views the company’s Q2 as worse than…
Smith & Nephew Earnings Call Transcript: Q2 2026
Q2 revenue growth was below expectations at 1.6%, with strong Sports Medicine and ENT offset by U.S. Orthopaedics and Advanced Wound Bioactives softness. Profitability remained robust, supported by efficiency savings and tariff refunds, and full-year profit guidance is maintained despite a reduced revenue outlook.
Smith & Nephew Quarterly report: Q2 2026
Smith & Nephew has published its Q2 2026 quarterly earnings report on August 4, 2026.
Smith & Nephew Slides: Q2 2026
Smith & Nephew has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
UK's Smith+Nephew cuts annual revenue expectations
British medical products company Smith+Nephew cut its full-year revenue growth forecast on Tuesday, as continued weakness in its orthopaedics unit in the U.S, its largest market, weighed ...
Smith & Nephew says TESSA system granded De Novo classification by FDA
Smith+Nephew announces it has been granted De Novo classification by the U.S. Food & Drug Administration for its TESSA Spatial Surgery System. Utilizing cutting-edge accelerated computing and AI techn...
Smith & Nephew price target lowered to 1,550 GBp from 1,600 GBp at Citi
Citi lowered the firm’s price target on Smith & Nephew to 1,550 GBp from 1,600 GBp and keeps a Buy rating on the shares.
New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single...
New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of ...
Smith & Nephew price target lowered to 1,333 GBp at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Smith & Nephew to 1,333 GBp from 1,507 GBp and keeps an Overweight rating on the shares.
Smith & Nephew Transcript: Investor update
The event showcased a robust innovation pipeline across wound care, sports medicine, orthopedics, and enabling technologies, with a focus on ASC efficiency and data-driven solutions. Key platforms like CORI, Landmark, AETOS, and TESSA are positioned to drive growth, supported by strong clinical evidence and surgeon advocacy.
Smith & Nephew Slides: Investor update
Smith & Nephew has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, ...
Smith & Nephew downgraded to Hold from Buy at Kepler Cheuvreux
Kepler Cheuvreux downgraded Smith & Nephew to Hold from Buy with a price target of 1,230 GBp, down from 1,462 GBp. The firm sees limited near-term catalysts for a re-rating…
Smith & Nephew downgraded to Hold from Buy at Kepler Cheuvreux
Kepler Cheuvreux downgraded Smith & Nephew to Hold from Buy.
Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF ♢ Patient Monitoring System, a data-driven pressure injury prevention platform d...
Smith & Nephew added to European Conviction List at Goldman Sachs
Goldman Sachs analysts added Smith & Nephew to the firm’s European Conviction List as part of its monthly update. The company’s guidance reset brings an opportunity to revisit a name…
Smith & Nephew Slides: Investor presentation
Smith & Nephew has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Smith & Nephew price target lowered to 1,550 GBp at Goldman Sachs
Goldman Sachs analyst Richard Felton lowered the firm’s price target on Smith & Nephew to 1,550 GBp from 1,700 GBp and keeps a Buy rating on the shares. The firm…